Stock Price, News, Quote and Profile of ELEVATION ONCOLOGY INC(NASDAQ:ELEV) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ELEVATION ONCOLOGY INC

NASDAQ:ELEV (4/22/2024, 7:00:01 PM)

After market: 3.91 -0.14 (-3.46%)

4.05

+0.25 (+6.58%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap197.03M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Elevation Oncology, Inc. is a precision oncology company. The company is headquartered in Boston, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 (SYSA1801 or CPO102), is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Claudin 18.2 is expressed across several solid tumor types, including many gastrointestinal cancers such as gastric, gastroesophageal junction and pancreatic cancer. Claudin 18.2 is also expressed in ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors. The firm is exploring opportunities through new or existing partnerships and business development opportunities to expand its novel oncology pipeline.

Company Info

ELEVATION ONCOLOGY INC

101 Federal Street, Suite 1900

Boston MASSACHUSETTS

P: 17163711125

CEO: Shawn Leland

Employees: 33

Website: https://elevationoncology.com/

ELEV News

12 days ago - InvestorPlace7 Top Stocks Under $7

Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now.

15 days ago - Elevation OncologyElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...